XML 32 R5.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash flows from operating activities:    
Net loss $ (17,755,000) $ (11,395,000)
us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract    
Depreciation 634,000 293,000
Amortization of debt discount and issuance costs 273,000 1,160,000
Amortization of right-of-use asset 59,000 12,000
Interest expense added to loan principal 435,000 0
Interest expense added to lease liability 1,032,000 913,000
Unrealized loss on derivative liability 220,000 0
Loss on early extinguishment of debt 5,331,000 0
Loss on equity method investments 0 169,000
Compensation charge for stock and share option awards 489,000 856,000
Changes in operating assets and liabilities:    
Accounts receivable (426,000) 116,000
Inventories (849,000) (344,000)
Prepaid expenses and other current assets (233,000) 125,000
Other assets (443,000) (242,000)
Accounts payable 816,000 216,000
Lease liabilities (53,000) (172,000)
Other accrued liabilities 599,000 743,000
Net cash used in operating activities (9,871,000) (7,550,000)
Cash flows from investing activities:    
Additions to property, plant and equipment and water programs (3,213,000) (1,748,000)
Contributions to equity-method investments 0 (100,000)
Net cash used in investing activities (3,213,000) (1,848,000)
Cash flows from financing activities:    
Net proceeds from issuance of stock 38,490,000 11,741,000
Dividend payments (2,553,000) (2,553,000)
Principal payments on long-term debt (15,088,000) (69,000)
Issuance costs of long-term debt (27,000) 0
Costs for early extinguishment of debt (600,000) 0
Taxes paid related to net share settlement of equity awards (261,000) 0
Net cash provided by financing activities 19,961,000 9,119,000
Net increase in cash, cash equivalents and restricted cash 6,877,000 (279,000)
Cash, cash equivalents and restricted cash, beginning of period 13,782,000 19,856,000
Cash, cash equivalents and restricted cash, end of period $ 20,659,000 $ 19,577,000